January 6, 2021
Researchers at the
University of Maryland School of Medicine (UMSOM) will participate in a Phase 3 clinical trial of an investigational COVID-19 vaccine to protect against SARS-CoV-2, the coronavirus causing COVID-19 that continues to impact millions of people around the world. The clinical trial will test the safety and effectiveness of NVX-CoV2373, being developed by U.S. biotechnology company Novavax, Inc., based in Gaithersburg, MD.
Clockwise from top left: Monica McArthur, Karen Kotloff, E. Albert Reece, and Kathleen Neuzil.
The vaccine trial is being conducted by researchers in UMSOM’s
Center for Vaccine Development and Global Health (CVD) as part of their National Institute of Allergy and Infectious Diseases (NIAID)-funded Vaccine Treatment and Evaluation Unit (VTEU), and the COVID-19 Prevention Network (CoVPN). It adds to the extensive COVID-19 vaccine research that has been underway on campus since early spring.
Researchers Begin Next Trial of Novavax COVID-19 Vaccine umaryland.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from umaryland.edu Daily Mail and Mail on Sunday newspapers.